IP Library Granted Patent US 11,124,547
Granted Patent B2
US 11,124,547 · App. 16/612,245 · Granted Sep 21, 2021

Antimicrobial type-II bacteriocins

Inventors: Nannette Y. Yount (San Juan Capistrano, CA); Michael R. Yeaman (Redondo Beach, CA)
Assignee: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
C07K14/32A61K38/164A61K45/06C07K14/195C07K14/325G16B30/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,124,547
App. No.
16/612,245
Granted
Sep 21, 2021
Kind
B2
Abstract

Computational systems and methods are described for identifying new type-ll bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-ll bacteriocin peptides are tested experimentally and show potent microbicidal activities. Further provided are the sequences of Newly identified type-ll bacteriocin peptides, and a method of treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of a peptide comprising an amino acid sequence disclosed.

Claims (10)

1. An isolated peptide comprising an amino acid sequence selected from the group consisting of FKVIVTDAGHYPREWGKQLGKWIGSKIK (SEQ ID NO: 5), KRNYSIEKYVKNY1DFIKKAIDIFRPMPI (SEQ ID NO: 6), KTIATNATYYPNKWAKSAGKWIASKIK (SEQ ID NO: 7), and QYDKTGYKIGKTVGTIVRKGFEIWSIFK (SEQ ID NO: 8), wherein the peptide is not longer than 45 amino acid residues in length.

2. The isolated peptide of claim 1 , wherein the peptide has antimicrobial activity.

3. The isolated peptide of claim 1 , wherein the peptide is not longer than 40 amino acid residues in length.

4. The isolated peptide of claim 1 , wherein the peptide is not longer than 35 amino acid residues in length.

5. The peptide of claim 1 , comprising one or more non-natural amino acid residue.

6. The composition comprising the peptide claim 1 and a pharmaceutically acceptable carrier.

7. The composition of claim 6 , further comprising an antimicrobial agent.

8. The composition of claim 7 , wherein the antimicrobial agent is selected from the group consisting of imipenem, ceftazidime, colistin, chloroquine, artemisinin, vancomycin and daptomycin.

9. A method of treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of the peptide of claim 1 comprising an amino acid sequence of Table 2 or 3 or SEQ ID NO:328 1884 or an amino acid derived from a sequence of Table 2 or 3 or SEQ ID NO:328 1884 with one amino acid substitution.

10. The method of claim 9 , wherein the infection is caused by a Gram-negative bacterium, a Gram-positive bacterium or a fungus.

Assignments (2)
CHANGE OF NAME Recorded Nov 18, 2020
From: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
To: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 054475/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2020
From: YOUNT, NANNETTE Y.; YEAMAN, MICHAEL R.
To: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 054316/0067 →
Continuity (2)
Provisional Application 62505015 · May 11, 2017
Related Publication 20200123209A1 · Apr 23, 2020